Upstream Bioprocessing Update


Alan Smith, Bellicum

Optimizing and automating scalable bioreactors and cell culture platforms for the reliable, high quality production of cells and viral vectors alike is an area of tremendous activity and innovation in cell & gene therapy. However, this is driven by a most pressing need to advance beyond current technological limitations in order to meet burgeoning demand and to better control manufacturing costs, timelines and quality.

  • Towards stable vector production platforms
  • Relative pros and cons of the latest automated upstream bioprocessing unit operations and all-in-one devices
  • Insights into scale-up success factors